The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension
(2005) In American Journal of Hypertension 18(2). p.227-234- Abstract
- Background: Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension. Methods: The study involved 20 subjects with type 2 DM who were already on 15 mg glibenclamide daily but were achieving poor glycemic control and who had either poorly controlled or newly diagnosed hypertension. In these patients, rosiglitazone (4 mg daily) was added to the existing therapeutic regimen for 26 weeks. At baseline and the end of the... (More)
- Background: Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension. Methods: The study involved 20 subjects with type 2 DM who were already on 15 mg glibenclamide daily but were achieving poor glycemic control and who had either poorly controlled or newly diagnosed hypertension. In these patients, rosiglitazone (4 mg daily) was added to the existing therapeutic regimen for 26 weeks. At baseline and the end of the treatment, subjects gave a 24-h urine collection for direct measurement of albumin and a spot specimen for determination of the albumin-to-creatinine ratio (ACR). Subjects also had a hyperinsulinemic euglycemic clamp and an ambulatory blood pressure (BP) monitoring. Results: At the end of the study, UAE was significantly reduced versus baseline, as measured either directly in the 24-h collection (22.4 +/- 4.6 v 13.8 +/- 3.0 mg/day, P <.05) or with ACR (20.9 +/- 3.8 v 14.0 +/- 2.8 mg/g, P < .05). The percentage changes in UAE (DeltaALB for the 24-h collection and AACR for ACR) correlated with the respective changes in IS (r = -0.64, P <.01 for DeltaALB and r -0.48, P =.05 for DeltaACR), systolic BP (r = 0.63,P <.01 and r = 0.58, P <.01 respectively), and diastolic BP (r 0.56, P <.05 and r = 0.50, P <.05 respectively). Conclusions: In this study, treatment of type 2 diabetic hypertensive patients with rosiglitazone significantly decreased UAE. Lowering of BP and improvement of IS should play roles in this UAE reduction. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/251001
- author
- Sarafidis, PA ; Lasaridis, AN ; Nilsson, Peter LU ; Hitoglou-Makedou, AD ; Pagkalos, EM ; Yovos, JG ; Pliakos, CI and Tourkantonis, AA
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- urinary albumin excretion, rosiglitazone, electrolytes, mellitus, type 2 diabetes, hypertension
- in
- American Journal of Hypertension
- volume
- 18
- issue
- 2
- pages
- 227 - 234
- publisher
- Oxford University Press
- external identifiers
-
- wos:000227394100013
- pmid:15752951
- scopus:14744285718
- ISSN
- 1941-7225
- DOI
- 10.1016/j.amjhyper.2004.09.010
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Internal Medicine Research Unit (013242520)
- id
- 55409180-c6dc-4391-a91c-6555fb1f8fc0 (old id 251001)
- date added to LUP
- 2016-04-01 12:11:34
- date last changed
- 2022-04-21 03:47:46
@article{55409180-c6dc-4391-a91c-6555fb1f8fc0,
abstract = {{Background: Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension. Methods: The study involved 20 subjects with type 2 DM who were already on 15 mg glibenclamide daily but were achieving poor glycemic control and who had either poorly controlled or newly diagnosed hypertension. In these patients, rosiglitazone (4 mg daily) was added to the existing therapeutic regimen for 26 weeks. At baseline and the end of the treatment, subjects gave a 24-h urine collection for direct measurement of albumin and a spot specimen for determination of the albumin-to-creatinine ratio (ACR). Subjects also had a hyperinsulinemic euglycemic clamp and an ambulatory blood pressure (BP) monitoring. Results: At the end of the study, UAE was significantly reduced versus baseline, as measured either directly in the 24-h collection (22.4 +/- 4.6 v 13.8 +/- 3.0 mg/day, P <.05) or with ACR (20.9 +/- 3.8 v 14.0 +/- 2.8 mg/g, P < .05). The percentage changes in UAE (DeltaALB for the 24-h collection and AACR for ACR) correlated with the respective changes in IS (r = -0.64, P <.01 for DeltaALB and r -0.48, P =.05 for DeltaACR), systolic BP (r = 0.63,P <.01 and r = 0.58, P <.01 respectively), and diastolic BP (r 0.56, P <.05 and r = 0.50, P <.05 respectively). Conclusions: In this study, treatment of type 2 diabetic hypertensive patients with rosiglitazone significantly decreased UAE. Lowering of BP and improvement of IS should play roles in this UAE reduction.}},
author = {{Sarafidis, PA and Lasaridis, AN and Nilsson, Peter and Hitoglou-Makedou, AD and Pagkalos, EM and Yovos, JG and Pliakos, CI and Tourkantonis, AA}},
issn = {{1941-7225}},
keywords = {{urinary albumin excretion; rosiglitazone; electrolytes; mellitus; type 2 diabetes; hypertension}},
language = {{eng}},
number = {{2}},
pages = {{227--234}},
publisher = {{Oxford University Press}},
series = {{American Journal of Hypertension}},
title = {{The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension}},
url = {{http://dx.doi.org/10.1016/j.amjhyper.2004.09.010}},
doi = {{10.1016/j.amjhyper.2004.09.010}},
volume = {{18}},
year = {{2005}},
}